All publications

Export 168 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
Hodcroft E, Hadfield J, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Leigh Brown A, UK HIV Drug Resistance Database.  2014.  HIV Virulence has not increased in the UK subtype B epidemic. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.
Chakraborty R., Smith CJ, Dunn DT, Green H, Duong T., Doerholt K., Riordan A., Lyall H., Tookey P, Butler K. et al..  2008.  HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.
El-Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak A, Tostevin A, Pillay D, Dunn DT et al..  2016.  HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother. 71(12)
Dolling D, Dunn DT, Geretti AM, Sabin CA.  2013.  HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.
de Oliveira T, Pillay D, Gifford RJM.  2010.  The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.
Le Vu S, Ratmann O, Delpech V, Brown AE, O Gill N, Tostevin A, Dunn D, Fraser C, Volz E.  2019.  HIV-1 transmission patterns in men who have sex with men: insights from genetic source attribution analysis.. AIDS Res Hum Retroviruses.
Bradshaw D, Dolling D, Booth C, Nelson M, Dunn DT, Asboe D.  2012.  How common is the mutation E138K in the UK? 18th Annual Conference of the British HIV Association, 18-20 April 2012.
I
Cane P A, Green H, Fearnhill E, Dunn DT.  2007.  Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 21:447-55.
Mulka L, Ragonnet-Cronin M, Tostevin A, Dunn DT, Leigh Brown A.  2017.  Identifying the sources of recent HIV infection in a UK cohort. 24th International HIV Dynamics and Evolution.
Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT.  2008.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.
Green H, Tilston P, Fearnhill E, Dunn DT, UK HIV Drug Resistance Database.  2007.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the UK. 13th Annual Conference of the British HIV Association, 25-28 April 2007.
Green H, Tilston P, Fearnhill E, Dunn DT, UK HIV Drug Resistance Database.  2007.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the UK. 2nd International Workshop on HIV Transmission, 26-28 August 2007.
Bansi L, Smith C, Phillips AN, Kirk S., Geretti AM, Johnson M, Mackie N, Post FA, Gazzard B, Dunn DT et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Mackie N, Dunn DT, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin CA, Geretti AM.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
Easterbrook P, Welz T, UK HIV Drug Resistance Database.  2006.  Impact of HIV-1 subtype on genotypic resistance to protease inhibitors in the United Kingdom. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006.
Bansi L, Geretti AM, Dunn DT, Sabin CA, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  The impact of resistance testing in ARV-naive patients: does it guide optimal therapy selection and improve long-term outcomes? British HIV Association 14th Annual Conference, 23-25 April 2008.
Gifford RJM, Kellam P, Dunn DT, Pillay D, UK HIV Drug Resistance Database.  2006.  The impact of structural and functional constraints acting at the nucleic acid level on the evolution of drug resistance in HIV-1. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.
Dunn DT, von Wyl V., Price H., Asboe D.  2010.  The impact of the 0-0 cell on measures of amino acid covariation. AIDS. 24:159-60.
Bansi L, Geretti AM, Dunn DT, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips AN et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
Geretti AM, White E, Beloukas A, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin CA, Dunn DT et al..  2016.  Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. International HIV Drug Resistance Workshop 2016.